Natera Slides 15% as Wider-Than-Expected Q3 Loss Overshadows Revenue Beat and Raised Outlook
NTRA sits 75% above its 52-week low of $181 on elevated volume (1.8× avg).
Summary
Natera delivered a big top-line beat — Q3 revenue of $793.98 million versus the $704.90 million consensus, up 34.08% year over year — and raised full-year 2026 revenue guidance to $3.01-$3.04 billion from $2.85-$2.91 billion, a $140 million lift at the midpoint. The problem is the bottom line: the loss of 42 cents a share was wider than the 29-cent loss analysts expected, even though it narrowed from 64 cents a year ago. Test volume grew 22.3% to about 1.09 million, with oncology up 60.9% to roughly 339,500 tests, and the company ended September with about $1.1 billion in cash. Shares were down 15.49% at $307.41 Friday, a sharp reaction for a company that just beat and raised — the market is punishing the wider loss and the cost structure rather than rewarding the revenue strength. This follows the prior evening's Q3 release and the simultaneous announcement that Solomon Moshkevich is taking over as CEO from Steve Chapman, so investors are digesting a new chief executive alongside the margin miss.
At the time of this announcement, NTRA was trading at $316.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $45.6B. The 52-week trading range was $181.00 to $437.41. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Benzinga.